Close Menu

SAN FRANCISCO (GenomeWeb) – Natera outlined its plans for entering the transplantation market this week, which include launching a clinical test in 2019 to detect acute rejection in kidney transplantation.

During a conference call with investors, Natera CEO Matt Rabinowitz discussed the firm's entrance into the transplantation market and highlighted progress it has made in the breast cancer market.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.